AstraZeneca Aiming To Extend Brilinta Use In PCI patients

 
• By Andrew McConaghie

AstraZeneca PLC’s newer oncology treatments are currently powering its growth, but the company is also looking to its cardiovascular, renal & metabolism (CVRM) portfolio to contribute, and a new study of Brilinta will help.

Anatomy of Human Heart
• Source: Shutterstock

More from Clinical Trials

More from R&D